{"protocolSection":{"identificationModule":{"nctId":"NCT02020616","orgStudyIdInfo":{"id":"14515"},"secondaryIdInfos":[{"id":"I6I-MC-LMRB","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes","officialTitle":"Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus"},"statusModule":{"statusVerifiedDate":"2019-09","overallStatus":"TERMINATED","whyStopped":"Lack of Efficacy","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-12"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-02","type":"ACTUAL"},"studyFirstSubmitDate":"2013-12-13","studyFirstSubmitQcDate":"2013-12-19","studyFirstPostDateStruct":{"date":"2013-12-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-09-27","resultsFirstSubmitQcDate":"2017-11-20","resultsFirstPostDateStruct":{"date":"2017-12-20","type":"ACTUAL"},"dispFirstSubmitDate":"2015-05-08","dispFirstSubmitQcDate":"2015-05-08","dispFirstPostDateStruct":{"date":"2015-05-25","type":"ESTIMATED"},"lastUpdateSubmitDate":"2019-09-25","lastUpdatePostDateStruct":{"date":"2019-10-08","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to investigate the safety and effectiveness of the study drug known as LY3053102 in participants with Type 2 diabetes mellitus. The study drug will be given in different doses as an injection under the skin. The study is expected to last up to 6 months for each participant. Participants may remain on stable-dose metformin as prescribed by their personal physician."},"conditionsModule":{"conditions":["Type 2 Diabetes Mellitus"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":60,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"LY3053102","type":"EXPERIMENTAL","description":"Stage 1: Escalating dose (7 milligrams \\[mg\\] up to 200 mg) of LY3053102 administered once a week by subcutaneous (SC) injection for 12 weeks. Stage 2: LY3053102 administered once a week by SC injection for 12 weeks","interventionNames":["Drug: LY3053102","Drug: Metformin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Stage 1 and Stage 2: Placebo to match LY3053102 administered by SC injection once a week for 12 weeks","interventionNames":["Drug: Placebo","Drug: Metformin"]},{"label":"Exenatide Extended-Release (ER)","type":"ACTIVE_COMPARATOR","description":"Stage 1 and Stage 2: Exenatide ER 2 mg given by SC injection once a week for 12 weeks","interventionNames":["Drug: Exenatide ER","Drug: Metformin"]},{"label":"LY3053102 + Exenatide ER","type":"EXPERIMENTAL","description":"Stage 2: LY3053102 administered by SC injection once a week for 12 weeks and exenatide ER 2 mg administered by SC injection once a week for 12 weeks","interventionNames":["Drug: LY3053102","Drug: Exenatide ER","Drug: Metformin"]}],"interventions":[{"type":"DRUG","name":"LY3053102","description":"Administered SC","armGroupLabels":["LY3053102","LY3053102 + Exenatide ER"]},{"type":"DRUG","name":"Exenatide ER","description":"Administered SC","armGroupLabels":["Exenatide Extended-Release (ER)","LY3053102 + Exenatide ER"]},{"type":"DRUG","name":"Placebo","description":"Administered SC","armGroupLabels":["Placebo"]},{"type":"DRUG","name":"Metformin","description":"Administered orally (PO)","armGroupLabels":["Exenatide Extended-Release (ER)","LY3053102","LY3053102 + Exenatide ER","Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for metformin use, washout of second oral anti-hyperglycemic medication (OAM), treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect.","timeFrame":"Baseline, Week 12"}],"secondaryOutcomes":[{"measure":"Percentage of Participants Achieving HbA1c <7.0% or HbA1c ≤6.5% at 12-Week Endpoint","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.","timeFrame":"Week 12"},{"measure":"Percentage of Participants That Require Rescue Therapy","description":"Percentage of participants that required \\>=1 rescue (blood glucose lowering) medications.","timeFrame":"Baseline through Week 12"},{"measure":"Change From Baseline in Body Weight at 12-Week Endpoint","description":"LS means were calculated using MMRM analysis adjusting for baseline HbA1c category, metformin use, washout of second OAM, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in 7-Point Blood Glucose Profile at 12-Week Endpoint","description":"7-Point Self-Monitored Blood Glucose profiles are measures of blood glucose concentration taken 7 times a day at morning pre-prandial, morning 2 hours postprandial, midday pre-prandial, midday 2 hours postprandial, evening pre-prandial, evening 2 hour postprandial, and bedtime. LS means were calculated using MMRM analysis adjusting for baseline HbA1c category, metformin use, washout of second OAM, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Lipids at 12-Week Endpoint","description":"Lipids includes: High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C), Triglycerides, and Cholesterol. LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Percentage of Participants With Anti-Drug Antibodies to LY3053102","description":"Percentage of participants with anti-LY3053102 antibody titre changes from baseline to the maximum postbaseline value.","timeFrame":"Baseline through Study Completion (Up to 6 Months)"},{"measure":"Percentage of Participants With Hypoglycemia","description":"Hypoglycemia was defined as any event meeting the criteria for documented symptomatic hypoglycemia, asymptomatic hypoglycemia, or probable symptomatic hypoglycemia.","timeFrame":"Baseline through Week 12"},{"measure":"Change From Baseline in Bone Metabolism at 12-Week Endpoint (Osteocalcin and Bone-Specific Alkaline Phosphatase [Bone-Specific ALP])","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Bone Metabolism at 12-Week Endpoint (Beta-Crosslaps and Procollagen 1 N-Terminal Propeptide [P1NP])","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Change From Baseline in Bone Mineral Density Markers at 12-Week Endpoint","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","timeFrame":"Baseline, Week 12"},{"measure":"Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC [τ,ss]) of LY3053102","description":"AUC (τ,ss) = area under the concentration versus time curve during one dosing interval at steady state, where the dosing interval (τ) = 168 hours.","timeFrame":"Predose, 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 hours post-dose"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria\n\n* Participants with type 2 diabetes mellitus for at least 6 months before entering the trial based on the disease diagnostic criteria (World Health Organization \\[WHO\\]) classification managed with diet or exercise alone or with a stable dose of metformin of at least 1000 mg/day for at least 60 days before screening or on metformin and an eligible second oral anti-hyperglycemic medication after a 60-day washout of the second oral anti-hyperglycemic medication\n* Women not of childbearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause\n* Have a hemoglobin A1c value of ≥7.0% and ≤10.5%, if on diet and exercise or diet, exercise, and metformin (stable dose of at least 1000 mg/day for at least 60 days), or have a hemoglobin A1c value of ≥7.0% and ≤9.5%, and are on an appropriate diet and exercise regimen, a stable dose of metformin and willing to discontinue a second oral anti-hyperglycemic medication\n* Have a body mass index ≥23 and ≤45 kilograms per square meter (kg/m\\^2)\n\nExclusion Criteria\n\n* Have used insulin for diabetic control for more than 6 consecutive days within 1 year prior to screening\n* Have used thiazolidinediones within 3 months, or any other drugs for treatment of hyperglycemia (except metformin) within 2 months, prior to the first week of the study\n* Have hepatitis B and/or positive hepatitis B surface antigen. hepatitis C or human immunodeficiency virus (HIV) and/or positive HIV antibodies\n* Have known or suspected cardiac autonomic neuropathy (for example, resting tachycardia or orthostatic hypotension), based on clinical signs, symptoms, or appropriate diagnostic testing\n* Have cardiac disease with functional status that is New York Heart Association Class II, III, or IV or in the last 6 months have had any of the following: a history of myocardial infarction , unstable angina, coronary artery bypass graft, percutaneous coronary intervention (diagnostic angiograms are permitted), transient ischemic attack, or cerebrovascular accident (for example, stroke)\n* Have poorly controlled hypertension, malignant hypertension, renal artery stenosis, and/or evidence of labile blood pressure including symptomatic postural hypotension. Doses of antihypertensive medications must be stable for 30 days prior to the first week of the study\n* Have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or an alanine transaminase or aspartate aminotransferase levels \\>2 times the upper limit of the reference range\n* Have evidence of hypothyroidism or hyperthyroidism based on clinical evaluation and/or an abnormal thyroid-stimulating hormone which, in the opinion of the investigator, would pose a risk to participant safety. Participants on a stable dose of thyroid replacement therapy may be eligible if they meet the other criteria\n* Have clinically significant peripheral vascular disease, or clinical evidence of active diabetic proliferative retinopathy, (known significant autonomic neuropathy) as evidenced by urinary retention, orthostatic hypotension, diabetic diarrhea or gastroparesis\n* Have an active or untreated malignancy or have been in remission from a clinically significant malignancy (other than basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n* Have impaired renal function\n* Have fasting triglycerides \\>500 milligrams per deciliter (mg/dL) at screening\n* Have experienced a keto-acidotic episode requiring hospitalization in the last 6 months\n* Have an electrocardiogram (ECG) considered to be indicative of cardiac disease\n* Have personal or family history of long QT syndrome, family history of sudden death in a first-degree relative before age 40, or personal history of unexplained syncope within the last year. Use of prescription or over-the-counter medications known to prolong the QT or QTc interval\n* Have a history of bone disease (including osteoporosis or unhealed fractures), evidence of osteoporosis (femoral neck or lumbar spine T-score \\<-2.5) determined by dual X-ray absorptometry (DXA) scan at screening, evidence of osteopenia (T-score between -1.0 and -2.5 at the femoral neck or lumbar spine) with a high risk of fracture based on risk factors or current active treatment of periodontal disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM -5PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Orange County Research Center","city":"Orange","state":"California","zip":"92868","country":"United States","geoPoint":{"lat":33.78779,"lon":-117.85311}},{"facility":"Miami Research Associates","city":"Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Compass Research","city":"Orlando","state":"Florida","zip":"32806","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Clinilabs, Inc (New York)","city":"New York","state":"New York","zip":"10019","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Dallas Diabetes Endocrine Center","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.","infoTypes":["STUDY_PROTOCOL","SAP","CSR"],"timeFrame":"Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.","accessCriteria":"A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.","url":"https://vivli.org/"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"The study was planned in 2 stages; Stage 1 evaluated up to 5 escalating parallel-dose groups. Stage 2, which was to evaluate participants stratified by Hemoglobin A1c (HbA1c), metformin therapy, and washout of a second oral anti-hyperglycemic medication (OAM) was not conducted because of inadequate efficacy at well-tolerated doses in Stage 1.","groups":[{"id":"FG000","title":"Placebo","description":"Placebo administered by subcutaneous injection (SC) once a week (Q1W) for 12 weeks"},{"id":"FG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC Q1W for 12 weeks."},{"id":"FG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC Q1W for 12 weeks."},{"id":"FG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC Q1W for 12 weeks."},{"id":"FG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC Q1W for 12 weeks."},{"id":"FG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC Q1W for 12 weeks."},{"id":"FG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC Q1W for 12 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"8"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"10"}]},{"type":"Received at Least One Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"7"},{"groupId":"FG004","numSubjects":"8"},{"groupId":"FG005","numSubjects":"8"},{"groupId":"FG006","numSubjects":"10"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"10"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"6"},{"groupId":"FG003","numSubjects":"6"},{"groupId":"FG004","numSubjects":"6"},{"groupId":"FG005","numSubjects":"3"},{"groupId":"FG006","numSubjects":"6"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"2"},{"groupId":"FG005","numSubjects":"5"},{"groupId":"FG006","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Early Termination Criteria Met","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Randomized in Error","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"All randomized participants who received at least 1 dose of study drug.","groups":[{"id":"BG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"BG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"BG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"BG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"BG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"BG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"BG006","title":"2 mg Exenatide ER","description":"2 mg Exenatide ER administered SC QW for 12 weeks"},{"id":"BG007","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"59"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"55.9","spread":"8.9"},{"groupId":"BG001","value":"57.3","spread":"4.9"},{"groupId":"BG002","value":"59.9","spread":"5.8"},{"groupId":"BG003","value":"56.3","spread":"6.0"},{"groupId":"BG004","value":"50.8","spread":"13.0"},{"groupId":"BG005","value":"54.6","spread":"8.3"},{"groupId":"BG006","value":"52.8","spread":"9.1"},{"groupId":"BG007","value":"55.3","spread":"8.5"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"24"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"4"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"35"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"35"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"24"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"11"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"44"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"2"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"}]}]}]},{"title":"Region of Enrollment","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"8"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"59"}]}]}]},{"title":"Baseline Hemoglobin A1c (HbA1c)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Percent of HbA1c","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8.39","spread":"0.80"},{"groupId":"BG001","value":"8.33","spread":"1.17"},{"groupId":"BG002","value":"7.93","spread":"0.81"},{"groupId":"BG003","value":"8.30","spread":"0.74"},{"groupId":"BG004","value":"9.40","spread":"1.43"},{"groupId":"BG005","value":"8.10","spread":"0.63"},{"groupId":"BG006","value":"8.50","spread":"1.03"},{"groupId":"BG007","value":"8.42","spread":"1.02"}]}]}]},{"title":"Baseline Fasting Plasma Glucose","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"milligram/deciliter (mg/dL)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"180.6","spread":"45.3"},{"groupId":"BG001","value":"178.6","spread":"44.3"},{"groupId":"BG002","value":"176.6","spread":"58.0"},{"groupId":"BG003","value":"173.3","spread":"39.6"},{"groupId":"BG004","value":"183.3","spread":"46.2"},{"groupId":"BG005","value":"185.9","spread":"50.6"},{"groupId":"BG006","value":"150.6","spread":"46.8"},{"groupId":"BG007","value":"174.9","spread":"46.5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) analysis adjusting for metformin use, washout of second oral anti-hyperglycemic medication (OAM), treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect.","populationDescription":"All randomized participants who received at least 1 dose of study drug, and who had baseline and post-baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"Percent of HbA1c","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC Q1W for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg Exenatide ER administered SC Q1W for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.49","spread":"0.33"},{"groupId":"OG001","value":"-0.70","spread":"0.40"},{"groupId":"OG002","value":"-0.75","spread":"0.44"},{"groupId":"OG003","value":"-0.22","spread":"0.43"},{"groupId":"OG004","value":"-0.48","spread":"0.40"},{"groupId":"OG005","value":"-0.52","spread":"0.47"},{"groupId":"OG006","value":"-1.43","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HbA1c <7.0% or HbA1c ≤6.5% at 12-Week Endpoint","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.","populationDescription":"All randomized participants who received at least 1 dose of study drug, and who had baseline and post-baseline data.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"title":"HbA1c <7.0%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"14.3"},{"groupId":"OG002","value":"40.0"},{"groupId":"OG003","value":"20.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"83.3"}]}]},{"title":"HbA1c ≤6.5%","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"66.7"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants That Require Rescue Therapy","description":"Percentage of participants that required \\>=1 rescue (blood glucose lowering) medications.","populationDescription":"All randomized participants who took at least 1 dose of study drug, and who had a baseline and a post-baseline measurement for the time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline through Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"12.5"},{"groupId":"OG003","value":"14.3"},{"groupId":"OG004","value":"0.0"},{"groupId":"OG005","value":"0.0"},{"groupId":"OG006","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight at 12-Week Endpoint","description":"LS means were calculated using MMRM analysis adjusting for baseline HbA1c category, metformin use, washout of second OAM, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug, and who had baseline and post-baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"kilogram (kg)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC Q1W for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 50 mg administered SC Q1W for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC Q1W for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC Q1W for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.1"},{"groupId":"OG001","value":"1.5","spread":"1.3"},{"groupId":"OG002","value":"0.0","spread":"1.4"},{"groupId":"OG003","value":"0.4","spread":"1.4"},{"groupId":"OG004","value":"-1.7","spread":"1.3"},{"groupId":"OG005","value":"-2.0","spread":"1.4"},{"groupId":"OG006","value":"-0.1","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 7-Point Blood Glucose Profile at 12-Week Endpoint","description":"7-Point Self-Monitored Blood Glucose profiles are measures of blood glucose concentration taken 7 times a day at morning pre-prandial, morning 2 hours postprandial, midday pre-prandial, midday 2 hours postprandial, evening pre-prandial, evening 2 hour postprandial, and bedtime. LS means were calculated using MMRM analysis adjusting for baseline HbA1c category, metformin use, washout of second OAM, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug, and who had baseline and post-baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligram/deciliter (mg/dL)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"}]}],"classes":[{"title":"Morning Meal (Post- minus Pre-prandial)","categories":[{"measurements":[{"groupId":"OG000","value":"-23.4","spread":"15.8"},{"groupId":"OG001","value":"-18.7","spread":"19.4"},{"groupId":"OG002","value":"-57.7","spread":"21.6"},{"groupId":"OG003","value":"-34.9","spread":"21.9"},{"groupId":"OG004","value":"4.7","spread":"18.3"},{"groupId":"OG005","value":"-26.8","spread":"25.8"},{"groupId":"OG006","value":"-47.9","spread":"19.4"}]}]},{"title":"Midday Meal (Post- minus Pre-prandial)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"22.4"},{"groupId":"OG001","value":"-31.3","spread":"27.5"},{"groupId":"OG002","value":"-55.0","spread":"29.2"},{"groupId":"OG003","value":"-24.7","spread":"29.2"},{"groupId":"OG004","value":"2.5","spread":"25.8"},{"groupId":"OG005","value":"-24.6","spread":"32.3"},{"groupId":"OG006","value":"-31.3","spread":"24.9"}]}]},{"title":"Evening Meal (Post- minus Pre-prandial)","categories":[{"measurements":[{"groupId":"OG000","value":"-18.8","spread":"20.8"},{"groupId":"OG001","value":"-11.1","spread":"25.8"},{"groupId":"OG002","value":"-46.5","spread":"27.5"},{"groupId":"OG003","value":"-25.9","spread":"27.9"},{"groupId":"OG004","value":"-39.0","spread":"24.1"},{"groupId":"OG005","value":"-61.3","spread":"31.4"},{"groupId":"OG006","value":"-4.9","spread":"24.2"}]}]},{"title":"Bedtime","categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":"19.1"},{"groupId":"OG001","value":"18.8","spread":"23.3"},{"groupId":"OG002","value":"-44.5","spread":"28.1"},{"groupId":"OG003","value":"-10.1","spread":"25.7"},{"groupId":"OG004","value":"4.9","spread":"22.1"},{"groupId":"OG005","value":"-13.0","spread":"30.8"},{"groupId":"OG006","value":"-53.6","spread":"23.5"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Lipids at 12-Week Endpoint","description":"Lipids includes: High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C), Triglycerides, and Cholesterol. LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug, and who had baseline and post-baseline data.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"mg/dL","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"title":"HDL-C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"2.2"},{"groupId":"OG001","value":"6.0","spread":"2.6"},{"groupId":"OG002","value":"9.3","spread":"2.9"},{"groupId":"OG003","value":"6.4","spread":"2.9"},{"groupId":"OG004","value":"6.0","spread":"2.6"},{"groupId":"OG005","value":"11.4","spread":"3.1"},{"groupId":"OG006","value":"-2.3","spread":"2.2"}]}]},{"title":"LDL-C","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":"10.4"},{"groupId":"OG001","value":"6.8","spread":"12.0"},{"groupId":"OG002","value":"-25.6","spread":"13.8"},{"groupId":"OG003","value":"-6.5","spread":"13.5"},{"groupId":"OG004","value":"-2.2","spread":"12.0"},{"groupId":"OG005","value":"-7.3","spread":"14.5"},{"groupId":"OG006","value":"-19.9","spread":"11.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Anti-Drug Antibodies to LY3053102","description":"Percentage of participants with anti-LY3053102 antibody titre changes from baseline to the maximum postbaseline value.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had evaluable immunogenicity.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline through Study Completion (Up to 6 Months)","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"2"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Hypoglycemia","description":"Hypoglycemia was defined as any event meeting the criteria for documented symptomatic hypoglycemia, asymptomatic hypoglycemia, or probable symptomatic hypoglycemia.","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline through Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0"},{"groupId":"OG001","value":"12.5"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"12.5"},{"groupId":"OG005","value":"12.5"},{"groupId":"OG006","value":"20.0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bone Metabolism at 12-Week Endpoint (Osteocalcin and Bone-Specific Alkaline Phosphatase [Bone-Specific ALP])","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"microgram/liter (ug/L)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"title":"Osteocalcin","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.1"},{"groupId":"OG001","value":"-0.7","spread":"1.3"},{"groupId":"OG002","value":"-1.7","spread":"1.3"},{"groupId":"OG003","value":"0.0","spread":"1.4"},{"groupId":"OG004","value":"-2.6","spread":"1.2"},{"groupId":"OG005","value":"-0.2","spread":"1.4"},{"groupId":"OG006","value":"0.3","spread":"1.0"}]}]},{"title":"Bone-Specific ALP","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.8"},{"groupId":"OG001","value":"-0.1","spread":"0.9"},{"groupId":"OG002","value":"-0.2","spread":"1.0"},{"groupId":"OG003","value":"-1.9","spread":"1.0"},{"groupId":"OG004","value":"-1.9","spread":"0.9"},{"groupId":"OG005","value":"-0.3","spread":"1.0"},{"groupId":"OG006","value":"-2.3","spread":"0.7"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bone Metabolism at 12-Week Endpoint (Beta-Crosslaps and Procollagen 1 N-Terminal Propeptide [P1NP])","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"title":"Beta-Crosslaps","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"-0.038","spread":"0.042"},{"groupId":"OG001","value":"-0.033","spread":"0.052"},{"groupId":"OG002","value":"-0.023","spread":"0.051"},{"groupId":"OG003","value":"0.001","spread":"0.053"},{"groupId":"OG004","value":"0.004","spread":"0.048"},{"groupId":"OG005","value":"0.031","spread":"0.054"},{"groupId":"OG006","value":"-0.010","spread":"0.040"}]}]},{"title":"P1NP","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"2.8"},{"groupId":"OG001","value":"-0.3","spread":"3.4"},{"groupId":"OG002","value":"0.9","spread":"3.5"},{"groupId":"OG003","value":"1.9","spread":"3.5"},{"groupId":"OG004","value":"-6.8","spread":"3.2"},{"groupId":"OG005","value":"-0.2","spread":"3.8"},{"groupId":"OG006","value":"2.3","spread":"2.9"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Bone Mineral Density Markers at 12-Week Endpoint","description":"LS means were calculated using MMRM analysis adjusting for metformin use, washout of second OAM, baseline HbA1c category, treatment, visit, and treatment-by-visit interaction as fixed effects, baseline as a covariate, and participant as a random effect (excludes data after rescue therapy).","populationDescription":"All randomized participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","unitOfMeasure":"milligram/square centimeter (mg/cm2)","timeFrame":"Baseline, Week 12","groups":[{"id":"OG000","title":"Placebo","description":"Placebo administered SC QW for 12 weeks"},{"id":"OG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"10"}]}],"classes":[{"title":"L1-L4 Intervertebral Space","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.6"},{"groupId":"OG001","value":"-0.4","spread":"1.9"},{"groupId":"OG002","value":"1.2","spread":"2.0"},{"groupId":"OG003","value":"1.0","spread":"2.1"},{"groupId":"OG004","value":"2.0","spread":"1.8"},{"groupId":"OG005","value":"1.6","spread":"2.1"},{"groupId":"OG006","value":"1.8","spread":"1.4"}]}]},{"title":"Neck of Femur","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.6"},{"groupId":"OG001","value":"-0.6","spread":"1.9"},{"groupId":"OG002","value":"-0.4","spread":"2.0"},{"groupId":"OG003","value":"-0.8","spread":"2.0"},{"groupId":"OG004","value":"-0.3","spread":"1.8"},{"groupId":"OG005","value":"-1.2","spread":"2.1"},{"groupId":"OG006","value":"-2.1","spread":"1.4"}]}]},{"title":"Total Hip","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"1.0"},{"groupId":"OG001","value":"-0.6","spread":"1.2"},{"groupId":"OG002","value":"-0.7","spread":"1.2"},{"groupId":"OG003","value":"-1.0","spread":"1.2"},{"groupId":"OG004","value":"0.1","spread":"1.1"},{"groupId":"OG005","value":"-0.7","spread":"1.3"},{"groupId":"OG006","value":"-1.0","spread":"0.8"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Area Under the Concentration Versus Time Curve During One Dosing Interval at Steady State (AUC [τ,ss]) of LY3053102","description":"AUC (τ,ss) = area under the concentration versus time curve during one dosing interval at steady state, where the dosing interval (τ) = 168 hours.","populationDescription":"All randomized participants who received at least 1 dose of study drug and had evaluable pharmacokinetics","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"microgram•hour/milliliter (µg•h/mL)","timeFrame":"Predose, 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 168 hours post-dose","groups":[{"id":"OG000","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG001","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG002","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG003","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks"},{"id":"OG004","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.6","spread":"32.1"},{"groupId":"OG001","value":"76.8","spread":"25.6"},{"groupId":"OG002","value":"190.0","spread":"47.3"},{"groupId":"OG003","value":"350.0","spread":"36.3"},{"groupId":"OG004","value":"917.0","spread":"35.1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"One participant was discontinued from the study before dosing due to meeting exclusion criteria.","eventGroups":[{"id":"EG000","title":"Placebo","description":"Placebo administered by SC QW for 12 weeks","seriousNumAffected":1,"seriousNumAtRisk":10,"otherNumAffected":6,"otherNumAtRisk":10},{"id":"EG001","title":"7 mg LY3053102","description":"7 mg LY3053102 administered SC QW for 12 weeks","seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":4,"otherNumAtRisk":8},{"id":"EG002","title":"15 mg LY3053102","description":"15 mg LY3053102 administered SC QW for 12 weeks","seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":4,"otherNumAtRisk":8},{"id":"EG003","title":"50 mg LY3053102","description":"50 mg LY3053102 administered SC QW for 12 weeks","seriousNumAffected":0,"seriousNumAtRisk":7,"otherNumAffected":4,"otherNumAtRisk":7},{"id":"EG004","title":"100 mg LY3053102","description":"100 mg LY3053102 administered SC QW for 12 weeks","seriousNumAffected":1,"seriousNumAtRisk":8,"otherNumAffected":7,"otherNumAtRisk":8},{"id":"EG005","title":"200 mg LY3053102","description":"200 mg LY3053102 administered SC QW for 12 weeks","seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":7,"otherNumAtRisk":8},{"id":"EG006","title":"2 mg Exenatide ER","description":"2 mg exenatide ER administered SC QW for 12 weeks","seriousNumAffected":0,"seriousNumAtRisk":10,"otherNumAffected":8,"otherNumAtRisk":10}],"seriousEvents":[{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]}],"otherEvents":[{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Ear congestion","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":9,"numAffected":6,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Frequent bowel movements","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Gastrointestinal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hiatus hernia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":6,"numAffected":4,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site discolouration","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site erosion","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":4,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":3,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":7,"numAffected":4,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Injection site haematoma","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site haemorrhage","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":7,"numAffected":5,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site nodule","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":4,"numAffected":2,"numAtRisk":7},{"groupId":"EG004","numEvents":4,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Injection site reaction","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Injection site urticaria","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Thirst","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hepatic steatosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":5,"numAffected":5,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Blood pressure systolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Cardiac stress test abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":3,"numAffected":3,"numAtRisk":10}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Fluid retention","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hypoglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":8,"numAffected":2,"numAtRisk":10}]},{"term":"Increased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":7},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":8},{"groupId":"EG005","numEvents":5,"numAffected":4,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Joint stiffness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":2,"numAffected":2,"numAtRisk":10}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Hypogeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Nasal congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Rhinitis allergic","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Sinus congestion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":1,"numAffected":1,"numAtRisk":10}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":10},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":7},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG006","numEvents":0,"numAffected":0,"numAtRisk":10}]}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"Stage 2, which was to evaluate participants stratified by HbA1c, metformin therapy, and washout of a second oral anti-hyperglycemic medication (OAM) was not conducted because of inadequate efficacy at well-tolerated doses in Stage 1."},"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-09","removedCountries":["Puerto Rico"]},"conditionBrowseModule":{"meshes":[{"id":"D003924","term":"Diabetes Mellitus, Type 2"}],"ancestors":[{"id":"D003920","term":"Diabetes Mellitus"},{"id":"D044882","term":"Glucose Metabolism Disorders"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D004700","term":"Endocrine System Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D008687","term":"Metformin"}],"ancestors":[{"id":"D001645","term":"Biguanides"},{"id":"D006146","term":"Guanidines"},{"id":"D000578","term":"Amidines"},{"id":"D009930","term":"Organic Chemicals"}]}},"hasResults":true}